ARCHIVES

Palbocicilib Doubles PFS In Phase II Trial to 20.2 Months

This article is from The Cancer Letter archive.

Vol. 37 No. 4 | April 25, 2014

Download PDF Visit The Full Archive

Related Articles

Letter In Response To Hadley; RFA Available

July 7, 1995

Cancer Society, Centers Explore Collaboration On Public Issued, Education, Information Activities

January 25, 1991

Who Writes NCI’s bypass Budget anyway>? Editor’s name Revealed

May 14, 1993

Reinventing NCI: Prevention Program Lacks Leadership, Reorganization Needed, Advisory Group Says

June 20, 1997

FOCR Report Offers Recommendations, Definitions for CER

May 22, 2009

Why Shouldn’t Scientific Issues Be Discussed In Open Meetings? Editorial

November 10, 1989